Natural Products Targeting Myocardial Fibrosis: Pharmacological Basis, Molecular Mechanisms and Translational Barriers
International Journal of Molecular Sciences · 07.08.2026 · 27 (16) · 7075
DOI: 10.3390/ijms27167075 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.08.2026. Verfasst von Tiantian Long und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal Univ…. Hauptthemen laut MEDLINE: Biological Products, Myocardium, Cardiomyopathies. Die Arbeit nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Students’ Platform for Innovation and Entrepreneurship Training Program, Postgraduate Innovation Project of Hunan Province.
Abstract (Originalsprache)
Myocardial fibrosis (MF) is a hallmark of pathological cardiac remodeling, driven by extracellular matrix (ECM) accumulation, fibroblast activation, and oxidative stress. Diverse natural products—notably alkaloids, flavonoids, terpenoids, and saponins—exhibit emerging antifibrotic potential. A comprehensive literature synthesis through July 2026 across PubMed, Web of Science, and Scopus categorized these agents by phytochemical class and disease models, delineating direct antifibrotic efficacy from indirect cardioprotection. Mechanistically, these compounds target TGF-β signaling, endothelial-to-mesenchymal transition (EndMT), autophagy/mitophagy, and ECM turnover. Robust preclinical evidence correlates with integrated histopathological assessment, specifically collagen and α-SMA quantification. However, translation remains impeded by model limitations, inadequate phytochemical standardization, and a critical paucity of clinical trials. Currently, no natural product holds clinical approval for MF. Future directives necessitate rigorous botanical authentication, pharmacokinetic/pharmacodynamic profiling, and adoption of human-relevant models, such as induced pluripotent stem cell-derived cardiomyocytes, to bridge the bench-to-bedside gap.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University Health Science Center, Hunan Normal University, Changsha 410013, China.
ORCID-Profile: Zihao Xie
Förderung
- National Natural Science Foundation of China
- National Students’ Platform for Innovation and Entrepreneurship Training Program
- Postgraduate Innovation Project of Hunan Province
Zitieren
APA
Long, T., Ma, J., Hu, W., Wang, Q., Xie, Z., Wu, S., & Wu, H. (2026). Natural Products Targeting Myocardial Fibrosis: Pharmacological Basis, Molecular Mechanisms and Translational Barriers. International Journal of Molecular Sciences, 27(16), 7075. https://doi.org/10.3390/ijms27167075
Vancouver
Long T, Ma J, Hu W, Wang Q, Xie Z, Wu S, et al. Natural Products Targeting Myocardial Fibrosis: Pharmacological Basis, Molecular Mechanisms and Translational Barriers. International Journal of Molecular Sciences. 2026;27(16):7075. doi:10.3390/ijms27167075
BibTeX
@article{Long2026,
author = {Long, Tiantian and Ma, Junchen and Hu, Weijun and Wang, Qiwen and Xie, Zihao and Wu, Sirong and Wu, Huaying},
title = {Natural Products Targeting Myocardial Fibrosis: Pharmacological Basis, Molecular Mechanisms and Translational Barriers},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7075},
doi = {10.3390/ijms27167075}
}
EUVIMED